Recent investigations have focused on the overlap of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopamine signaling. While GCGR agonists are increasingly employed for addressing type 2 diabetes, their potential effects on reinforcement circuits, specifically governed by dopamine system